Biogen will present data on its treatments and investigational treatments for people with multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer’s disease at the upcoming American Academy of Neurology (AAN) annual meeting in Boston.
“Biogen’s commitment to improving outcomes for people living with MS spans more than two decades, during which time we’ve fundamentally changed the treatment of the disease,” Biogen Executive Vice President and Chief Medical Officer Alfred Sandrock said. “We are now applying our expertise in neurology to discover and develop new therapies to address some of the most challenging and complex diseases of the brain.”
Biogen will present real-world evidence on MS treatments TECFIDERA (dimethyl fumarate) and TYSABRI (natalizumab) which demonstrate the importance of early treatment of the disease. The will also show new data on the clinically meaningful efficacy of its SMA treatement, SPINRAZA (nusinersen), which is the first and only FDA-aaproved SMA treatment. Biogen will also present Phase 1b data of its investigational Alzheimer’s disease treatment aducanumab, which was first presented in December 2016.
“The data from our MS, SMA and Alzheimer’s disease programs reflect our desire to advance the understanding of these diseases and make a meaningful difference in the lives of patients,” Sandrock said.
The 69th AAN annual meeting is set for April 22-28 at the Boston Convention and Exhibition Center.
Alerts Sign-up